Adjuvanted influenza vaccines

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 1, 2012, Pages 59-66

  Principi, Nicola ^a   Esposito, Susanna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SALT; AS 03; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; ISCOM; ISCOMATRIX; LIPOSOME; MIFAMURTIDE; PHOSPHORYL LIPID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIROSOME; VIRUS SIALIDASE; AS03 ADJUVANTED VACCINE; COAT PROTEIN; CYTOSINE GUANINE DINUCLEUTIDE CONTAINING OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; MF59 ADJUVANTED VACCINE; OLIGODEOXYNUCLEOTIDE; PAPAYA MOSAIC VIRUS COAT PROTEIN; TOLL LIKE RECEPTOR AGONIST; TRIVALENT INACTIVATE INFLUENZA VACCINE; VAX 125; VIROSOME VACCINE; VIRUS VACCINE;

ADJUVANT THERAPY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; CROSS REACTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE STERILE ABSCESS; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; MALAISE; MYALGIA; NARCOLEPSY; NONHUMAN; REVIEW; SEROCONVERSION; SUBCUTANEOUS NODULE; SWELLING; VIRUS LIKE AGENT; VIRUS STRAIN; ABSCESS; DRUG FORMULATION; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; DRUG TOLERANCE; EDEMA; ERYTHEMA; EXPERIMENTAL ANIMAL; FEVER; IMMUNE RESPONSE; PATIENT SAFETY; SINGLE DRUG DOSE; SKIN REDNESS; SLEEP DISORDER;

EID: 84861806285     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.1.18011     Document Type: Review

References (86)

1. van Essen GA, Palache AN, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 2003; 21:1780-5; PMID:12686094; http://dx.doi.org/10.1016/ S0264-410X(03)00072-0
2. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr., Griffin MR. The effect of influenza on hospitalization, outpatient visits, and courses of antibiotic use. N Engl J Med 2000; 342:225-31; PMID:10648763; http://dx.doi.org/10.1056/ NEJM200001273420401
3. Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003; 22(Suppl):S207-10; PMID:14551476; http://dx.doi.org/10.1097/01.inf.0000092188.48726.e4
4. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59(No. RR-8):1-5; PMID:20075837
5. European CDC. Seasonal influenza vaccines 2011. Available at http://ecdc.europa.eu/en/healthtopics/seasonal-influenza/vaccines/Pages/ influenza- vaccination.aspx.
6. Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill 2010; 15:44; PMID:21087586
7. Esposito S, Marchisio P, Principi N. The global state of influenza in children. Pediatr Infect Dis J 2008; 27(Suppl):S149-53; PMID:18955890; http://dx.doi.org/10.1097/INF.0b013e31818a542b
8. Piedra PA, Glezen WP. Influenza in children: epidemiology, immunity, and vaccines. Semin Pediatr Infect Dis 1991; 2:140-6.
9. Palache AM, Beyer WE, Lüchters G, Völker R, Sprenger MJ, Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 1993; 11:892-908; PMID:8212834; http://dx.doi.org/10.1016/ 0264-410X(93)90375-8
10. Principi N, Esposito S, Marchisio P. Present and future of influenza prevention in pediatrics. Expert Opin Biol Ther 2011; 11:641-53; PMID:21366499; http://dx.doi.org/10.1517/14712598.2011.562495
11. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010; 28(Suppl. 3):C25-36; PMID:20713254; http://dx.doi.org/10.1016/j.vaccine.2010.07.021
12. Nauta JJ, Beyer WEP, Osterhaus ADME. On the relationship between antibody response to influenza vaccination, seroprotection and clinical protection from influenza. Biologicals 2009; 37:216-21; PMID:19268607; http://dx.doi.org/10. 1016/j.biologicals.2009.02.002
13. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemoagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 2010; 10:18; PMID:20210985
14. Beyer WEP, Nauta JJP, Palache AM, Giezeman KM, Osterhaus ADME. Immunogenicity and safety of inactivated influenza vaccines in primed population: a systematic literature review and meta-analysis. Vaccine 2011; Epub May 30.
15. Morefield GL, Sokolovska A, Jiang D, Hogen Esch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005; 23:1588-95; PMID:15694511; http://dx.doi.org/10. 1016/j.vaccine.2004.07.050
16. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122-6; PMID: 18496530; http://dx.doi.org/10.1038/nature06939
17. Eickhoff TC, Myers MG. Workshop summary: aluminum in vaccines. Vaccine 2002; 20(Suppl. 3): S1-4; PMID:12184358; http://dx.doi.org/10.1016/S0264- 410X(02)00163-9
18. Jefferson T, Rudin M, Di Pietrantoni C. Adverse events after immunization with aluminium- containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004; 4:84-90; PMID:14871632; http://dx.doi.org/10.1016/S1473- 3099(04)00927-2
19. Podda A, Del Giudice G. MF-59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197-204; PMID: 12899571; http://dx.doi.org/10.1586/14760584.2.2.197
20. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant System in vaccines: concepts, achievement and perspectives. Expert Rev Vaccines 2007; 6:723-9; PMID:17931153; http://dx.doi.org/10.1586/14760584.6.5.723
21. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503; PMID:21029960; http://dx.doi.org/10.1016/j. immuni.2010.10.002
22. Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R & Family Medicine Group of Pianiga. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007; 25:3955-61; PMID:17383057; http://dx.doi.org/10.1016/j.vaccine.2007.02.045
23. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19:2673-80; PMID:11257408; http://dx.doi.org/10.1016/S0264-410X(00)00499-0
24. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135-40; PMID:11599686; http://dx.doi.org/10.1023/A:1017919305501
25. Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21:1268-74; PMID: 12559808; http://dx.doi.org/10.1016/S0264-410X(02)00401-2
26. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhanced the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49:177-84; PMID:12679609; http://dx.doi.org/10.1159/000069172
27. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563-71; PMID:19561422; http://dx.doi.org/10.1097/INF.0b013e31819d6394
28. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009; 27:6291-5; PMID:19840662; http://dx.doi.org/10.1016/j.vaccine.2009.02.004
29. Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, et al. Immunogenicity and safety of influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59 adjuvanted vaccine versus non adjuvanted vaccine. Clin Vaccine Immunol 2011; Epub Jun 29.
30. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10.1056/NEJMoa0907650
31. Arguedas A, Soley C, Abdelnour A, Sales V, Lindert K, Della Cioppa G, et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 2011; 7:58-66; PMID: 21285531; http://dx.doi.org/10.4161/hv.7.1.13411
32. Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63:1062-7; PMID:21425247; http://dx.doi.org/10.1002/acr.20465
33. Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 2011; 127:e1161-8; PMID: 21464195; http://dx.doi.org/10. 1542/peds.2010-1920
34. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, et al. MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines. Sci Transl Med 2011; 3:85ra48; PMID:21632986; http://dx.doi.org/10.1126/scitranslmed.3002336
35. Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin Ther 2010; 32:2186-97; PMID: 21316535; http://dx.doi.org/10.1016/S0149-2918(11)00024-5
36. Vesikari T, Karvonen A, Tilman S, Barkowski A, Montomoli E, Banzhoff A, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010; 126:e762-70; PMID:20819892; http://dx.doi.org/10.1542/peds.2009-2628
37. Stephenson I, Gust I, Kierry MP, Pervikov Y. Development and evolution of pandemic influenza vaccines. Lancet Infect Dis 2006; 6:71-2; PMID: 16439326; http://dx.doi.org/10.1016/S1473-3099(06)70364-4
38. Martin JT. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 1997; 25:209-13; PMID:9236054; http://dx.doi.org/10.1006/biol.1997.0086
39. Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005; 133:687-93; PMID:16050515; http://dx.doi.org/10.1017/ S0950268805003936
40. Esposito S, Meregalli E, Daleno C, Ghio L, Tagliabue C, Valzano A, et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011; 26:2018-24; PMID:20974645; http://dx.doi.org/10.1093/ndt/gfq657
41. Esposito S, D'Angelo E, Daleno C, Peia F, Scala A, Serra D, et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with b-thalassemia major. Vaccine 2010; 28:7825-8; PMID:20888873; http://dx.doi.org/10.1016/j.vaccine.2010.09.058
42. Esposito S, Selicorni A, Daleno C, Valzano A, Cerutti M, Galeone C, et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. Hum Vaccine 2011;7: Epub June 1.
43. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10:639-51; PMID:20218923; http://dx.doi.org/10.1517/14712591003724662
44. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26:3209-22; PMID:18462843; http://dx.doi.org/10. 1016/j.vaccine.2008.03.093
45. Parretta E, Ianniello B, Ferrazin F, Rossi F, Capuano A. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine 2011; 29:3708-13; PMID:21406267; http://dx.doi.org/ 10.1016/j.vaccine.2011.02.097
46. Levine PH, Richardson PK, Zolfaghari L, Cleary SD, Geist CE, Potolicchio S, et al. A study of Gulf War veterans with a possible deployment-related syndrome. Arch Environ Occup Health 2006; 61:271-8; PMID: 17967750; http://dx.doi.org/10.3200/AEOH.61.6.271-278
47. Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction? Eur J Intern Med 2010; 21:70-3; PMID:20206873; http://dx.doi.org/10.1016/j.ejim.2009.12.001
48. Tsai TF, Crucitti A, Nacci P, Nicolay U, Cioppa GD, Ferguson J, et al. Explorations of clinical trials and pharmacovigilance databases of MF59(1)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011; Epub May 2.
49. Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27:7428-35; PMID:19683087; http://dx.doi.org/10.1016/j.vaccine.2009.07.102
50. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009; 9:1057-71; PMID:19555313; http://dx.doi.org/10.1517/14712590903066695
51. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90; PMID:19856521; http://dx.doi.org/10.1016/j. vaccine.2009.01.040
52. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649; PMID:20508026; http://dx.doi.org/10.1136/bmj.c2649
53. Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248-56; PMID:21288852; http://dx.doi.org/10.1093/cid/ciq104
54. Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, et al. Immunogenicity profile of a 3.75-mg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:1054-62; PMID:21450995; http://dx.doi.org/10.1093/infdis/ jiq174
55. Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28:5837-44; PMID:20600478; http://dx.doi.org/10.1016/j.vaccine.2010.06.065
56. Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, Merino JM, et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011; 29:4353-61; PMID:21504774; http://dx.doi.org/10.1016/j.vaccine.2011.04.011
57. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine:case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011; 342:c7297; PMID: 21292718; http://dx.doi.org/10.1136/bmj.c7297
58. Eurosurveillance editorial team.Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy. Euro Surveill2011; 16 pii:19904.
59. World Health Organization. Global Advisory Committee on Vaccine Safety. Statement on nacolepsy and vaccination. 21 April 2011. Available at: http://www.who.int/vaccine-safety/topics/influenza/pandemic/h1n1-safety- assessing/narcolepsy-statement/en/index.html
60. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002; 20(Suppl 5):B17-23; PMID:12477413; http://dx.doi.org/10.1016/S0264-410X(02)00512-1
61. Huckriede A, Bungener I, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosomal concept for influenza vaccine. Vaccine 2005; 23:S26-38; PMID:16026906; http://dx.doi.org/10.1016/j.vaccine.2005.04.026
62. Calcagnile S, Zuccotti GV. The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 2010; 10:191-200; PMID:20088714; http://dx.doi.org/10. 1517/14712590903431014
63. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ, Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344:160-3; PMID:7912766; http://dx.doi.org/10.1016/S0140-6736(94)92758-8
64. Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B, et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997; 15:1675-9; PMID: 9364699; http://dx.doi.org/10.1016/S0264-410X(97)00087-X
65. Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging 2001; 13:38-43; PMID:11292151
66. Baldo V, Menegon T, Bonello C, Floreani A, Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001; 19:3472-5; PMID:11348713; http://dx.doi.org/10.1016/S0264-410X(01)00060-3
67. Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ, Lindenstrøm T, Enouf V, van der Werf S, et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 2011; Epub Jun 29.
68. Even-Or O, Samira S, Rochlin E, Balasingam S, Mann AJ, Lambkin-Williams R, et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 2010; 28:6527-41; PMID:20412874; http://dx.doi.org/10.1016/j.vaccine.2010.04.011
69. Tremblay MH, Majeau N, Gagné ME, Lecours K, Morin H, Duvignaud JB, et al. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J 2006; 273:14-25; PMID:16367744; http://dx.doi.org/10.1111/j.1742-4658.2005.05033.x
70. Denis J, Majeau N, Acosta-Ramirez E, Savard C, Be'dard MC, Simard S, et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007; 363:59-68; PMID: 17320136; http://dx.doi.org/10.1016/j.virol.2007.01.011
71. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008; 26:3395-403; PMID:18511159; http://dx.doi.org/10.1016/j.vaccine.2008.04.052
72. Savard C, Guérin A, Drouin K, Bolduc M, Laliberté- Gagné ME, Dumas MC, et al. Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles. PLoS ONE 2011; 6:e21522; PMID: 21747909; http://dx.doi.org/10.1371/journal.pone.0021522
73. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 1987; 165:64-9; PMID:3794607; http://dx.doi.org/10.1084/jem.165.1.64
74. Hocart MJ, Mackenzie JS, Stewart GA. The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol 1989; 70:2439-48; PMID:2778440; http://dx.doi.org/10.1099/0022-1317- 70-9-2439
75. Mallick AI, Parvizi P, Read LR, Nagy E, Berhboudi S. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine 2011; 29:1657-65; PMID: 21195078; http://dx.doi.org/10.1016/j.vaccine.2010.12.046
76. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93:2879-83; PMID:8610135; http://dx.doi.org/10.1073/pnas.93.7.2879
77. Mallick AI, Parvizi P, Read LR, Nagy E, Behboudi S, Sharif S. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine 2011; 29:1657-65; PMID:21195078; http://dx.doi.org/10.1016/j.vaccine.2010.12.046
78. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigen presentation of membrane proteins from enveloped viruses. Nature 1984; 308:457-60; PMID:6709052; http://dx.doi.org/10.1038/ 308457a0
79. Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009; 87:371-6; PMID: 19381160; http://dx.doi.org/ 10.1038/icb.2009.21
80. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101:10697-702; PMID:15252201; http://dx.doi.org/10.1073/pnas. 0403572101
81. Brown LE. The role of adjuvants in vaccines for seasonal and pandemic influenza. Vaccine 2010; 28:8043-5; PMID:20849874; http://dx.doi.org/10.1016/j. vaccine.2010.09.024
82. Sanders MT, Deliyannis C, Pearse MJ, McNamara MK, Brown LE. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine 2009; 27:2475-82; PMID: 19368789; http://dx.doi.org/10.1016/j.vaccine. 2009.02.054
83. Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 2008; 3:e2257; PMID:18493310; http://dx.doi.org/10.1371/journal.pone.0002257
84. Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, et al. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS ONE 2011; 6:e20928; PMID: 21687743; http://dx.doi.org/10.1371/journal.pone.0020928
85. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011; 29:4897-902; PMID:21596084; http://dx.doi.org/10.1016/j.vaccine.2011.05.001
86. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum saltand TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183:6186-97; PMID:19864596; http://dx.doi.org/10.4049/ jimmunol.0901474